1-3 of 3
Catherine Couturier, PharmD
Close
Sort by
Journal Articles

Evaluation of Experimental Retreatment and Prolonged Therapy with Subcutaneous (SC) Bortezomib in Patients (Pts) with Multiple Myeloma in First or Second Relapse, a Randomized, Controlled, Phase 3 Study

Michele Cavo, MD, Marco Gobbi, MD, Anna Potamianou, MD PhD, Marjolein Lahaye, MSc, Catherine Couturier, PharmD, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3328.
https://doi.org/10.1182/blood.V128.22.3328.3328
Published: 2016
Journal Articles

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Meletios A. Dimopoulos, MD, Robert Z. Orlowski, M.D., Ph.D, Thierry Facon, MD, Pieter Sonneveld, MD, Ph.D, Kenneth C. Anderson, MD, Meral Beksac, MD, Lotfi Benboubker, MD, Huw Roddie, MBChB, Ph.D, Anna Potamianou, MD, Catherine Couturier, PharmD, Huaibao Feng, Ph.D, Ozlem Ataman, MD, Ph.D, Helgi van de Velde, Paul G. Richardson, MD
Journal: Blood
Blood (2013) 122 (21): 3177.
https://doi.org/10.1182/blood.V122.21.3177.3177
Published: 2013
Journal Articles

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Meletios Athanasios Dimopoulos, MD, Meral Beksac, MD, Lotfi Benboubker, MD, PhD, Huw Roddie, MBChB, PhD, Nathalie Allietta, Esther Broer, Catherine Couturier, PharmD, Marie-AndreĢe Mazier, DESS, Ralf Angermund, MD, Thierry Facon, MD
Journal: Blood
Blood (2011) 118 (21): 1861.
https://doi.org/10.1182/blood.V118.21.1861.1861
Published: 2011